AR058749A1 - Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento - Google Patents
Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complementoInfo
- Publication number
- AR058749A1 AR058749A1 ARP060105794A ARP060105794A AR058749A1 AR 058749 A1 AR058749 A1 AR 058749A1 AR P060105794 A ARP060105794 A AR P060105794A AR P060105794 A ARP060105794 A AR P060105794A AR 058749 A1 AR058749 A1 AR 058749A1
- Authority
- AR
- Argentina
- Prior art keywords
- risk
- polymorphism
- amd
- patient
- age
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract 9
- 208000002780 macular degeneration Diseases 0.000 title abstract 9
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 108010053085 Complement Factor H Proteins 0.000 abstract 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 abstract 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 abstract 1
- 229940093817 Convertase inhibitor Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004304 visual acuity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos para identificar a un paciente en riesgo de desarrollar DMRE mediante la identificacion de la presencia del polimorfismo Y402H o de otras variantes de riesgo en el gen el factor H de complemento. Además métodos para el tratamiento de personas que tienen DMRE o que se encuentran en riesgo de desarrollar DMRE como resultado e poseer el polimorfismo Y402H u otras variantes de riesgo en el gen del factor H de complemento. Reivindicacion 1: Un método para inhibir la pérdida de la agudeza visual asociada con la degeneracion macular relacionada con la edad (DMRE) en un paciente que posee DMRE o que se encuentra en riesgo de desarrollar DMRE debido a la presencia de un polimorfismo Y402H o de otra variante de riesgo, comprendiendo dicho método: a) identificar dicho polimorfismo Y402H u otra variante de riesgo en dicho paciente mediante i) la obtencion de una muestra de tejido de dicho paciente; y ii) el ensayo de dicha muestra de tejido en cuanto a la presencia del polimorfismo Y402H o de otra variante de riesgo, en donde la presencia del polimorfismo Y402H o de otra variante de riesgo indica un incremento en el riesgo de desarrollo de DMRE o en la progresion de la DMRE seca a la DMRE humeda; b) administrar a un paciente a quien se identifico en la etapa (a) precedente como poseyendo el polimorfismo Y402H u otra variante de riesgo una cantidad terapéuticamente efectiva de una composicion que comprende un inhibidor de C3-convertasa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75313505P | 2005-12-22 | 2005-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058749A1 true AR058749A1 (es) | 2008-02-20 |
Family
ID=38218828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105794A AR058749A1 (es) | 2005-12-22 | 2006-12-26 | Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070149616A1 (es) |
| EP (1) | EP1963529A2 (es) |
| JP (1) | JP2009521506A (es) |
| KR (1) | KR20080087814A (es) |
| CN (1) | CN101346473A (es) |
| AR (1) | AR058749A1 (es) |
| AU (1) | AU2006330501B2 (es) |
| BR (1) | BRPI0620249A2 (es) |
| CA (1) | CA2631958A1 (es) |
| TW (1) | TW200731984A (es) |
| WO (1) | WO2007076437A2 (es) |
| ZA (1) | ZA200805148B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2009015087A2 (en) * | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
| MX2010003630A (es) * | 2007-10-02 | 2010-04-21 | Potentia Pharmaceuticals Inc | Administracion sostenida de analogos de compstatina desde geles. |
| WO2009059318A2 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Genes and polymorphisms associated with amd |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| DK3359555T3 (da) | 2015-10-07 | 2024-03-25 | Apellis Pharmaceuticals Inc | Doseringsplaner |
| GB2553252B (en) | 2016-01-20 | 2019-07-31 | Vitrisa Therapeutics Inc | Aptamers that block the catalytic cleft of complement Factor D |
| CN115951066A (zh) * | 2016-02-29 | 2023-04-11 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| IL314891B1 (en) | 2017-04-07 | 2025-11-01 | Apellis Pharmaceuticals Inc | Dosing regimens and related compositions and methods |
| AU2018386304B2 (en) | 2017-12-15 | 2023-12-07 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043268A (en) * | 1990-05-04 | 1991-08-27 | The Trustees Of Princeton University | Substrates and inhibitors for prenyl cysteine methyltransferase enzymes |
| EP1221918B1 (en) * | 1999-10-21 | 2005-03-16 | Alcon Inc. | Sub-tenon drug delivery |
| WO2001084149A2 (en) * | 2000-04-29 | 2001-11-08 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| WO2004073608A2 (en) * | 2003-02-20 | 2004-09-02 | Alcon, Inc. | Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
| NZ608860A (en) * | 2005-02-14 | 2014-10-31 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| CN101325963B (zh) * | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
-
2006
- 2006-12-21 WO PCT/US2006/062485 patent/WO2007076437A2/en not_active Ceased
- 2006-12-21 BR BRPI0620249-7A patent/BRPI0620249A2/pt not_active Application Discontinuation
- 2006-12-21 TW TW095148168A patent/TW200731984A/zh unknown
- 2006-12-21 CN CNA2006800488907A patent/CN101346473A/zh active Pending
- 2006-12-21 JP JP2008547771A patent/JP2009521506A/ja active Pending
- 2006-12-21 CA CA002631958A patent/CA2631958A1/en not_active Abandoned
- 2006-12-21 AU AU2006330501A patent/AU2006330501B2/en not_active Ceased
- 2006-12-21 US US11/614,595 patent/US20070149616A1/en not_active Abandoned
- 2006-12-21 KR KR1020087016825A patent/KR20080087814A/ko not_active Ceased
- 2006-12-21 EP EP06846751A patent/EP1963529A2/en not_active Withdrawn
- 2006-12-26 AR ARP060105794A patent/AR058749A1/es unknown
-
2008
- 2008-06-12 ZA ZA2008/05148A patent/ZA200805148B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009521506A (ja) | 2009-06-04 |
| ZA200805148B (en) | 2009-12-30 |
| WO2007076437A3 (en) | 2008-01-31 |
| US20070149616A1 (en) | 2007-06-28 |
| CN101346473A (zh) | 2009-01-14 |
| KR20080087814A (ko) | 2008-10-01 |
| AU2006330501B2 (en) | 2012-04-05 |
| AU2006330501A1 (en) | 2007-07-05 |
| TW200731984A (en) | 2007-09-01 |
| WO2007076437A2 (en) | 2007-07-05 |
| BRPI0620249A2 (pt) | 2011-11-08 |
| EP1963529A2 (en) | 2008-09-03 |
| CA2631958A1 (en) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066292A1 (es) | Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario | |
| AR058749A1 (es) | Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento | |
| WO2009012468A3 (en) | Differential expression of micrornas in nonfailing versus failing human hearts | |
| AR116859A2 (es) | Métodos para tratar la esclerosis múltiple progresiva | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| BRPI0518289A2 (pt) | mÉtodos e composiÇÕes para o tratamento de desordens oculares | |
| WO2008042231A3 (en) | Compositions and methods for evaluating and treating heart failure | |
| AR057631A1 (es) | Composiciones y metodos para incrementar la sensibilidad a insulina | |
| EP3447491A3 (en) | Diagnosis and treatments relating to th2 inhibition | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| MX2017014204A (es) | Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2. | |
| WO2009021521A3 (en) | Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression | |
| TW200833842A (en) | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| Martinez et al. | Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| Hatta et al. | Nicotine reduced MMP‐9 expression in the primary porcine tenocytes exposed to cyclic stretch | |
| Freese et al. | Environmental enrichment reduces cocaine neurotoxicity during cocaine-conditioned place preference in male rats | |
| DE602006011607D1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| NO20080781L (no) | GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer | |
| WO2008155390A3 (en) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. | |
| WO2006047475A3 (en) | Detection and analysis of ophthalmically-relevant fluorescent molecules | |
| MX2020007619A (es) | Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones. | |
| ATE550443T1 (de) | Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |